Skip to main content
. 2022 Jul 15;76(3):e240–e249. doi: 10.1093/cid/ciac498

Table 1.

Overview of Sample Characteristics for the Study Population

Sample Type Subgroup No. of Samples Median dT, Days (IQR) No. (%) of Females Median Age, Years (IQR) History of Immunosuppressive Condition or Medication, No. (%)
Convalescent WT (adults) 30 104 (94–119) 14 (47) 62 (51–69) 0 (0)
WT (children) 20 124 (116–129) 7 (35) 11 (7–14) 0 (0)
Alpha 30 88 (47–104) 12 (40) 56 (42–65) 14 (47)
Delta 6 18 (10–23) 5 (83) 65 (56–73) 4 (67)
Infected and vaccinated 25 54 (23–91) 16 (64) 55 (48–59) 1 (4)
Vaccinated A/A (1–2 mo) 30 49 (48–52) 20 (67) 64 (60–66) 2 (7)
A/A (4–6 mo) 30 154 (146–158) 23 (77) 55 (48–60) 0 (0)
M/M (1–2 mo) 30 51 (48–54) 20 (67) 59 (49–61) 1 (3)
M/M (4–6 mo) 16 139 (131–145) 9 (56) 70 (51–83) 1 (6)
P/P (1–2 mo) 30 51 (49–54) 20 (67) 58 (52–66) 1 (3)
P/P (4–6 mo) 30 152 (141–160) 25 (83) 38 (30–53) 0 (0)
A/M 20 153 (150–154) 16 (80) 41 (29–56) 0 (0)
A/P 20 151 (144–157) 19 (95) 48 (42–56) 0 (0)
P/P/P 20 14 (14–26.5) 13 (65) 33 (29–44) 2 (12)
Negative 15 8 (53) 37 (29–41) 0 (0)

Abbreviations: A/A, 2-dose AZD1222; A/M, first dose AZD1222, second dose mRNA-1273; A/P, first dose AZD1222, second dose BNT162b2; dT, time post-infection/last vaccination dose; IQR, interquartile range; M/M, 2-dose mRNA-1273; P/P, 2-dose BNT162b2; P/P/P, 3-dose BNT162b2; WT, wild-type (B.1 isolate).